Recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsværd, Denmark) was specifically developed for use in hemophilia A and hemophilia B patients with corresponding factor inhibitors . The Food and Drug Administration (FDA) approved rFVIIa in the United States in 1999 for management of bleeding episodes in patients with congenital hemophilia A or B with inhibitors (auto-antibodies to coagulation factors VIII and IX). The label was subsequently expanded to include patients with acquired hemophilia, congenital factor VII deficiencies and inherited platelet disorders.
Zaher G, Adam S, Azher F, Hindawi S, Damanhouri G (2015) Validation of a Scoring System for Prediction of Clinical Outcome in the Off-label Use of Recombinant Factor VIIa. J Hematol Thrombo Dis S1:003. doi:10.4172/2329-8790.1000S1003